Allergic Reactions
7
2
2
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
6 treatments under study, led by Thromboelastogram
Research Leaders
7 sponsors active, led by Wyeth is now a wholly owned subsidiary of Pfizer
Related Conditions
Often studied with 6 related conditions
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 7 trials
100.0%
+13.4% vs benchmark
14%
1 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 4 completed trials
Clinical Trials (7)
Maximum Lysis on Thromboelastography as a Marker of Systemic Severity in Acute Allergic Reactions
Study Evaluating the Safety and Efficacy of Neffy or Intramuscular Adrenalin in Patients With Allergic Reactions After Oral Food Challenge or Allergen Immunotherapy
Determination of Blomia Tropicalis Allergen Extract in Prick Test Units
Study Evaluating Chlorpheniramine Maleate Liquid in Children and Adolescents
Study Evaluating Brompheniramine Maleate Liquid in Children and Adolescents
Study of Valortim® (MDX-1303) and Its Selected Formulation Components Percutaneous Use
Study to Describe the Allergic Reactions to Factor IX in Patients With Hemophilia B
Research Network
Common Treatments
- Thromboelastogram1
- Allergenic Extract1
- Epinephrine1
- Valortim And Selected Components1
- Chlorphenamine1
Active Sponsors
- Wyeth is now a wholly owned subsidiary of Pfizer3
- Mayo Clinic1
- National Institute of Allergy and Infectious Diseases (NIAID)1
- ARS Pharmaceuticals, Inc.1
- PharmAthene, Inc.1
Top Investigators
Hospital Universitario de Canarias
Sponsor Medical Monitor
Kansas City Allergy and Asthma
Related Conditions
- Biomarkers Blood1
- Allergy To Blomia Tropicalis1
- Anaphylaxis1
- Hemophilia B1
- Allergy1